Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare the safety and effectiveness of Pipeline Embolization Device to coil embolization for the treatment of coilable wide-necked intracranial aneurysms
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Coil embolization | Active Comparator | Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed. Stents are not allowed in this arm. |
|
| Pipeline | Experimental | Placement of 1 or more Pipeline Embolization Device(s)(PED) into the parent artery at the target aneurysm. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pipeline Embolization Device (PED) | Device | 1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Effectiveness: Proportion of subjects whose target aneurysm shows complete occlusion on angiogram with <=50% stenosis of the parent artery. Safety: Proportion of subjects with ipsilateral major stroke or neurologic death. | 180 days |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of complete target aneurysm occlusion | 1, 3 and 5 years | |
| Incidence of ipsilateral major stroke | 180 days | |
| Change in modified Rankin scale (MRS) |
Not provided
Inclusion Criteria:
Age 21 to 75 years, inclusive
Patient has a single target IA that:
If target IA has a neck >4 mm, at least 2 of 3 members of an independent expert committee (IEC) have confirmed that coil embolization with optional adjunctive techniques** has a very high likelihood of procedural success (i.e., coil placement and retention)
Subject has provided written informed consent using the IRB-approved consent form
Subject has the necessary mental capacity to participate and is willing and able to comply with protocol requirements
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Fiorella, MD, PhD | Barrow Neurologic Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | United States | ||
| SUNY Stony Brook |
Not provided
| ID | Term |
|---|---|
| D002532 | Intracranial Aneurysm |
| ID | Term |
|---|---|
| D020765 | Intracranial Arterial Diseases |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Coil embolization | Device | Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed. |
|
| 180 days, 1, 3 and 5 years |
| Incidence of device-related adverse events | 180 days, 1, 3 and 5 years |
| Change from baseline in neurologic signs or symptoms related to the target aneurysm | 180 days |
| Stony Brook |
| New York |
| 11794 |
| United States |
| D009422 | Nervous System Diseases |
| D000783 | Aneurysm |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |